Geisinger Medical Center is First in Pennsylvania to Treat Cancer Patients with Accuray Radixact® System
Geisinger welcomed the Radixact System in a ribbon-cutting ceremony led by the chairman of radiation oncology at
According to the
The Radixact System was designed to improve patient care by providing clinical teams with the tools they need to make the planning and delivery of radiation straightforward, efficient and effective for standard indications like breast and head and neck cancers, and complex treatments such as total marrow irradiation.
- The Radixact System delivers the same highly conformal and homogeneous dose distribution faster than the previous TomoTherapy platform, with a higher dose rate (1000 MU/minute) and imaging time that is up to 66 percent faster. A combination of higher dose output and faster image acquisition can shorten treatment times, while improving the patient experience
- A fully-integrated, automated adaptive solution, PreciseART® Adaptive Radiation Therapy Software, makes adaptive radiotherapy simple and practical. The software enables physicians to easily decide when adaptation of radiation delivery during the course of treatment would be beneficial due to changes in tumor size and patient anatomy
- The PreciseRTX® Retreatment Option accelerates and automates the re-planning process to make re-treatment more efficient for practices and more effective for patients in those cases where, unfortunately, cancer has recurred and additional radiation treatments are necessary
- The CTrue™ IR (Iterative Reconstruction) image guidance software improves soft-tissue contrast and reduces noise, enhancing image quality, while maintaining the same low imaging dose and fast reconstruction time as earlier versions of the software. Patient workflows are also more streamlined, facilitating the delivery of precise treatments more quickly, for more patients
"We are excited to partner with the
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
About Accuray
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical experiences and results, patient experiences, and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's limited long-term clinical data supporting the safety and efficacy of its products and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contacts
Public Relations Director,
+1 (408) 789-4426
bkaplan@accuray.com
MSLGROUP
+1 (781) 684-6610
accuray@mslgroup.com
______________________________________
1 U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on
View original content to download multimedia:http://www.prnewswire.com/news-releases/geisinger-medical-center-is-first-in-pennsylvania-to-treat-cancer-patients-with-accuray-radixact-system-300914464.html
SOURCE